|
|
Post by lennymnkd on Mar 22, 2022 6:55:15 GMT -5
|
|
|
|
Post by peppy on Mar 22, 2022 7:04:48 GMT -5
"MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas Hofmann, MD, PhD, will participate in the Cantor Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am (PT)." I think what rare orphan lung disease has is the ability to be covered by health insurance. Technosphere made for it. Listed, UTHR to take care of the managed care and government contracts..... insurance coverage, and prescriptions.  |
|
